Sulfadimethoxine
Spezifikationen
122-11-2CAS-Nummer
204-523-7EG-Nummer
4-amino-N-(2,6-dimethoxypyrimidin-4-yl)benzenesulfonamideIUPAC-Name
C12H14N4O4SChemische Formel
310.33 g/molMolekulargewicht
sulfadimethoxine; 122-11-2; Sulphadimethoxine; Albon; Sulfadimethoxydiazine; Madribon; 4-amino-N-(2,6-dimethoxypyrimidin-4-yl)benzenesulfonamide; Sulfadimetoxina; Benzenesulfonamide, 4-amino-N-(2,6-dimethoxy-4-pyrimidinyl)-; 4-Amino-N-(2,6-dimethoxy-4-pyrimidinyl)benzenesulfonamide; Sulfadimethoxinum; 2,6-Dimethoxy-4-sulfanilamidopyrimidine; 2,4-Dimethoxy-6-sulfanilamido-1,3-diazine; 6-Sulfanilamido-2,4-dimethoxypyrimidine; DTXSID1023607; Di-Methox; SULFAMED-G; 4-amino-N-(2,6-dimethoxypyrimidin-4-yl)benzene-1-sulfonamide; 2,6-Dimethoxy-4-(p-aminobenzenesulfonamido)pyrimidine; NSC-683544; 30CPC5LDEX; NSC-757860; CHEBI:32161; N(sup 1)-(2,6-Dimethoxy-4-pyrimidinyl)sulfanilamide; DTXCID303607; N(1)-(2,6-dimethoxy-4-pyrimidinyl)sulfanilamide; Sulforal; SulfaMed; Albon Tablets; Albon Bolus; Albon or Agribon; Sulfasol Soluble Powder; RefChem:56063; Albon Oral Suspension 5%; Di-Methox Injection 40%; Bactrovet Tablets 250 mg; SULFADIMETHOXINE 40%; sulfadimethoxine oral solution; Medacide-SDM Injection 10%; Sulfadimethoxine Soluble Powder; Sulfadimethoxine Injection 40%; Albon S.R. (Sustained Release); J01ED01; Sulfadimethoxine Solution 12.5%; Bactrovet Oral Suspension 12.5%; Sulfadimethoxine 12.5% Oral Solution; Di-Methox Concentrated Solution 12.5%; Sulfadimethoxine Concentrated Solution 12.5%; AGRIBON Concentrated Solution 12.5%, ALBON Concentrated Solution 12.5%; 204-523-7; Sulfadimethoxin; Sulfadimetoxin; Dimetazina; Agribon; Arnosulfan; Theracanzan; Bactrovet; Deposul; Diasulfa; Diasulfyl; Dinosol; Madriqid; Maxulvet; Memcozine; Metoxidon; Omnibon; Radonin; Roscosulf; Abcid; Fuxal; Sudine; Sulxin; Symbio; Dimethoxysulfadiazine; Madrigid; Madroxin; Madroxine; Neostrepal; Persulfen; Scandisil; Sulfastop; Sulfoplan; Dorisul; Redifal; Sulfadimetossina; NSC 683544; Agribon (TN); Abcid (TN); MFCD00057345; N1-(2,6-Dimethoxy-4-pyrimidinyl)sulfanilamide; MLS000069720; NSC683544; Sulfanilamide, N(sup 1)-(2,6-dimethoxy-4-pyrimidinyl)-; NCGC00016375-01; Neostreptal; CAS-122-11-2; SMR000017367; Suldixine; Solfadimetossina; Sulfadimethoxine-13C6; Sulfadimetoxine; Sulfadimoxine; [(4-aminophenyl)sulfonyl](2,6-dimethoxypyrimidin-4-yl)amine; Sulfabon; Sulfadimethoxine [JAN]; Solfadimetossina [DCIT]; Sulfadimetossina [Italian]; Sulfadimethoxinum [INN-Latin]; Sulfadimetoxina [INN-Spanish]; SR-01000000227; EINECS 204-523-7; UNII-30CPC5LDEX; BRN 0306856; Ultrasulfon; Lasibon; Mecozine; Sumbio; Sdmo; CCRIS 9326; Albon (veterinary); Prestwick_979; Sulfadimethoxine CRS; Rofenaid (Salt/Mix); 4-Amino-N-(2,6-dimethoxy-4-pyrimidinyl)benzolsulfonamid; Spectrum_001408; Sulfadimethoxine [USP:INN:BAN:JAN:NF]; Opera_ID_1856; Prestwick0_000728; Prestwick1_000728; Prestwick2_000728; Prestwick3_000728; Spectrum2_001419; Spectrum3_001454; Spectrum4_000442; Spectrum5_001221; CBKinase1_000256; CBKinase1_012656; Epitope ID:122237; Sulfadimethoxine (Standard); Cambridge id 5251398; Oprea1_486812; Oprea1_495206; SCHEMBL93845; Sulfadimethoxine (JAN/USP); BSPBio_000656; BSPBio_002947; KBioGR_000824; KBioSS_001888; SULFADIMETHOXINE [MI]; 5-25-13-00290 (Beilstein Handbook Reference); MLS000103402; MLS000104965; MLS001148602; CHEMBL62193; DivK1c_000088; SPECTRUM1501144; SULFADIMETHOXINE [INN]; SPBio_001498; SPBio_002595; BPBio1_000722; orb1226763; orb1309840; orb3025072; Sulfadimethoxine [EP monograph]; component of Prazil (Salt/Mix); component of Primor (Salt/Mix); SCHEMBL29363944; SULFADIMETHOXINE [MART.]; GTPL12638; HMS500E10; HY-B0337R; KBio1_000088; KBio2_001888; KBio2_004456; KBio2_007024; KBio3_002447; 4-Sulfa-2,6-dimethoxypyrimidine; MSK4042; SULFADIMETHOXINE [USP-RS]; SULFADIMETHOXINE [WHO-DD]; component of Maxutrim (Salt/Mix); component of Rofenaid (Salt/Mix); NINDS_000088; HMS1570A18; HMS1921J15; HMS2090P11; HMS2092F21; HMS2097A18; HMS2230L05; HMS3370K02; HMS3655H05; HMS3714A18; HMS5080H09; Pharmakon1600-01501144; component of Trivalbon (Salt/Mix); SMSSF-0041038; HY-B0337; MSK4042-1000DM; Tox21_110405; BBL023015; CCG-38972; EBC-04407; MSK4042-100M; NSC757860; s1962; SBB001275; STK018258; SULFADIMETHOXINE [GREEN BOOK]; AKOS000485038; Tox21_110405_1; DB06150; KS-5335; SULFADIMETHOXINE [USP IMPURITY]; 4-Sulfanilamido-2,6-dimethoxypyrimidine; IDI1_000088; SMP2_000079; SULFADIMETHOXINE [USP MONOGRAPH]; 2,4-Dimethoxy-6-Sulfanilamidopyrimidine; NCGC00016375-02; NCGC00016375-03; NCGC00016375-04; NCGC00016375-05; NCGC00016375-06; NCGC00016375-09; NCGC00016375-10; NCGC00024020-03; NCGC00024020-04; AC-10998; ST007535; SBI-0051656.P002; Sulfadimethoxine for peak identification CRS; 6-Sulfanilamido-2,4-dimethoxy-1,3-diazine; AB00052219; NS00000200; SW149624-4; 2,4-Dimethoxy-6-sulfanilamido-1,3-pyrimidine; D01142; EN300-761486; H10770; AB00052219-15; AB00052219-17; AB00052219_18; AB00052219_19; Sulfadimethoxine 1000 microg/mL in Acetonitrile; Sulfadimethoxine Solution in Methanol, 100ug/mL; F859367; Q4921678; SR-01000000227-2; SR-01000000227-4; Sulfadimethoxine, VETRANAL(TM), analytical standard; Sulfanilamide, N1-(2,6-dimethoxy-4-pyrimidinyl)-; 4-(p-Aminobenzenesulfonamido)-2,6-dimethoxypyrimidine; BRD-K71125014-001-05-7; BRD-K71125014-001-07-3; BRD-K71125014-001-17-2; BRD-K71125014-001-26-3; BRD-K71125014-001-27-1; N(Sup1)-(2,6-Dimethoxy-4-pyrimidinyl)sulfanilamide; Z56763920; F1443-4783; Sulfadimethoxine Solution in DMSO/Methanol, 1000ug/mL; Sulfadimethoxine, analytical standard, >=98.5% (TLC); 4-amino-N-[2,6-bis(methyloxy)pyrimidin-4-yl]benzenesulfonamide; Sulfadimethoxine, European Pharmacopoeia (EP) Reference Standard; p-aminophenyl(2,6-dimethoxy-4-pyrimidinylamino)(oxo)-lambda-sulfaniumolate; Sulfadimethoxine, United States Pharmacopeia (USP) Reference Standard; Sulfadimethoxine for peak identification, European Pharmacopoeia (EP) Reference StandardSynonyme
